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Background: Tumor associated antigens are useful in colorectal cancer (CRC) management. The ribosomal P
proteins (P0, P1, P2) play an important role in protein synthesis and tumor formation. The immunogenicity of the
ribosomal P0 protein in head and neck, in breast and prostate cancer patients and the overexpression of the
carboxyl-terminal P0 epitope (C-22 P0) in some tumors were reported.
Methods: Sera from 72 colorectal tumor patients (67 malignant and 5 benign tumors) were compared with 73 healthy
donor sera for the presence of antibodies to CEA, EGFR, ErbB2 and ribosomal P proteins by western blotting or ELISA.
Expression of the C-22 P0 epitope on tissues and colon cancer cells was determined by immunoperoxidase staining
and indirect immunofluorescence/western blotting, respectively, employing MAb 2B2. Biological effects of MAb 2B2 on
colon cancer cells were assessed by the Sulforhodamine B cell proliferation assay, trypan blue exclusion test and
cleaved caspase-3 detection. Fisher’s exact test was used to compare the number of auto-antibodies positive patients
with healthy donors. Variation in the C-22 P0 expression, and in the number of apoptotic cells was evaluated by
Student’s t-test. Variation in cell survival and cell death was evaluated by Newman-Keuls test.
Results: No significant humoral response was observed to CEA, EGFR and ErbB2 in CRC patients. Conversely, 7 out of
67 CRC patient sera reacted to ribosomal P proteins. The prevalence of P proteins auto-antibodies in CRC patients was
significant. Five patients showed restricted P0 immunoreactivity, while two patients reacted simultaneously to all P
proteins. The C-22 P0 epitope was homogenously expressed both in malignant tumors and the adjacent mucosa, but
the intensity of expression was higher in the tumor. Starved colon cancer cells showed a higher C-22 P0 epitope
plasma membrane expression compared to control cells. MAb 2B2 inhibited colon cancer cell growth and induced cell
death in a dose dependent manner.
Conclusions: Our study shows a spontaneous humoral immune response to ribosomal P0 protein in CRC patients and
the inhibition of in vitro cancer cell growth after C-22 P0 epitope targeting. The ribosomal P0 protein might be a useful
immunological target in CRC patients.
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Colorectal cancer (CRC) is the most common form of
cancer among those that affect the gastrointestinal tract
and represents the third most frequent cancer in men
and the second in women [1,2]. Despite advances in
diagnosis and therapy, the survival rate of CRC depends
on the stage being 90% for stage I and II, and <11% for
stage IV [1,3]. The process of CRC carcinogenesis is a
multistep process characterized by mutations of several
genes, which lead to an invasive and drug resistant-
phenotype of the tumor [4-8]. The identification of
molecular and immunological targets is essential for
improving diagnostic and therapeutic strategies for CRC
management.
Tumor antigens expressed by cancer cells are able to
elicit spontaneous immune response in cancer patients
[9]. Many auto-antibodies have been proposed as diag-
nostic or prognostic markers in cancer patients although
they recognize self-antigens that are overexpressed in tu-
mors [10-14]. It is worth of note that the repertoire of
auto-antibodies found in cancer patients partly covers
that detected in patients with autoimmune diseases [9].
In addition, auto-antibodies represent useful serological
markers in the diagnosis of the autoimmune disease [9].
The immune identification of self-antigens in cancer pa-
tients might have significant repercussions that go beyond
the discovery of novel biomarkers, since auto-antibodies
found in cancer patients can target crucial molecules in-
volved in the carcinogenesis process [15].
Several tumor associated antigens have been shown to
be useful in CRC patients. Among them, the most com-
mon is the carcinoembryonic antigen (CEA), a glycosyl-
ated membrane-bound protein of 180 kDa expressed in
a high percentage of several carcinomas, including colo-
rectal, gastric, pancreatic, non-small cell lung and breast
carcinomas. The high level tumor expression of CEA
and its release in the blood make CEA suitable for using
it as tumor marker, especially in patients with CRC
[16,17]. Other CRC tumor markers include circulating
RNA, MicroRNA, mutated DNA (APC, K-RAS, p53),
aberrant methylated markers, CA 19-9, TPA, CA 72-4
and cytokeratin fragments [18-20]. The expression of the
epidermal growth factor receptor (EGFR) and human
epidermal growth factor receptor 2 (HER2 or ErbB2) are
associated with poor prognosis in sporadic CRC, thus
representing two important prognostic markers in addition
to be employed for targeted-therapy [21,22].
The ribosomal P proteins (P0, 38 kDa; P1, 19 kDa; P2,
17 kDa) are involved in the formation of the ribosomal
stalk of the 60 S ribosomal subunit in eukaryotic cell, in
which they regulate protein synthesis [23-27]. Recently,
we demonstrated the spontaneous immunogenicity of
the ribosomal P0 protein in head and neck, in breast
and prostate cancer patients and the overexpression ofthe carboxyl-terminal epitope of P0 (C-22 P0) in head
and neck and breast carcinomas [28-30]. The immuno-
dominant C-22 P0 epitope was found to be located
within the 22 amino acid C-terminal peptide shared by
all three P proteins [31,32]. P0 exists as a free protein in
the cytoplasm and on the surface of cancer cells [28,33]
and appears to promote tumor formation [34]. Auto-
antibodies against P proteins have been identified for the
first time in systemic lupus erythematosus (SLE) [35]. It
was also found that the mRNA level of the P0 was
greater in primary colon carcinoma than in paired adja-
cent normal colon epithelium [36].
In the present study, we investigated the humoral im-
mune response to ribosomal P proteins, CEA, EGFR and
ErbB2 in CRC patients and the expression of the C-22
P0 epitope in colon cancer tissues. We also assessed the
C-22 P0 epitope expression in two colon adenocarcin-
oma cell lines and the in vitro effect of a monoclonal
antibody (MAb 2B2) which recognizes this epitope on
the growth of colon cancer cells.
Methods
Cell lines, antibodies and proteins
Colon adenocarcinoma cells (HT29 and SW260) were
maintained in RPMI 1640 containing 10% fetal bovine
serum, 100 U/ml penicillin and 100 μg/ml streptomycin
(complete medium). Cells were grown at 37°C in a hu-
midified incubator with an atmosphere of 5% CO2.
NIH3T3 cells encoding normal rat Neu (LTR-Neu) have
been previously characterized and kindly provided by
Dr. Eddi Di Marco (Istituto Tumori di Genova) [37].
NIH3T3 cells transfected with expression vectors for hu-
man coding sequences of human ErbB family receptors,
including LTR-EGFR and LTR-ErbB2, as well as anti-
EGFR and anti-ErbB2 antibodies were previously de-
scribed and kindly provided by Dr. Matthias Kraus [38].
MAb 2B2 is an IgG2a monoclonal antibody, which rec-
ognizes the C-22 P0 epitope [28]. Prokaryotic recombin-
ant proteins (P0, P1, P2 and GST), and method of
determining the MAb isotype were previously described
[28,29,39]. Protein concentration was determined by
Bradford protein assay (Bio-Rad, Hercules, CA, USA) [40].
Carcinoembryonic antigen (CEA) was purchased from
Vitro Diagnostic Inc (Littleton, CO). The anti-CEA MAb
R4 was previously described [41]. Sulforhodamine B, goat
anti-human and anti-mouse IgG peroxidase-conjugated
antibodies were purchased from Sigma (Milan, Italy). Goat
anti-mouse IgG Alexa fluor-488-conjugated antibody was
purchased from Life Technologies™ Molecular Probes
(Oregon, USA). Anti-human CD3 and anti-human CD20
antibodies were purchased from Ventana Medical System
Inc (Tucson, AZ, USA). The anti-activated caspase-3 poly-
clonal antibody was purchased from Cell Signalling Tech-
nology (MA, USA). The purified mouse IgG2a (kappa)
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Corporation (West Chester, PA, USA) and used as
control.
Tissues and sera
Tissues and sera of patients were obtained according to
the ethical guidelines of the Policlinico of Tor Vergata
“PTV”, Rome. Sera from 72 patients with colorectal tu-
mors (colon carcinoma, n = 39; rectal carcinoma, n = 16;
sigmoid carcinoma, n = 5; recto-sigmoid carcinoma, n =
7; colon adenoma, n = 5) were collected and compared
with 73 healthy donor sera, collected from blood donors
from the University of Rome “Sapienza” transfusion cen-
ter [24 women (mean age: 45.2 ± 14.4) and 49 men
(mean age: 47.2 ± 10.7)]. Sera were obtained after in-
formed consent and kept at -20°C until evaluation. The
clinical stage of cancer patients included stage I (n = 15),
stage IIa (n = 22), stage IIb (n = 2), stage IIIa (n = 1),
stage IIIb (n = 21), stage IIIc (n = 4) and stage IV (n = 2).
Tissue specimens from 23 cancer patients were also ob-
tained. Adjacent normal mucosa was informative in 17
specimens.
Detection of anti-Rib-P antibodies
DRG® Anti-Rib-P ELISA kit (EIA-3582, DRG Instru-
ments GmbH, Germany) was employed for detection of
IgG auto-antibodies against ribosomal P proteins (P0,
P1, P2). The analysis was performed according to the
manufacturers’ instructions. Values of anti-rib-P anti-
bodies above 10 U/ml were above the cut-off and thus
were considered positive.
Western blotting
Electrophoresis of purified recombinant P-GST (P0, P1,
P2), GST and CEA proteins (0.5 μg⁄lane) as well as
NIH3T3 and NIH-LTR-EGFR and LTR-ErbB2 cell ex-
tracts (100 μg/lane) was carried out in denaturing 10-
12% SDS polyacrylamide gels. Following electrophoresis,
proteins were transferred to nitrocellulose membranes
at 40 V for 1 h. After blocking in a washing solution
(1% Tween-20 in PBS, pH 7.6) containing 5% non-
fat dry milk, membranes were incubated overnight
at 4°C with either human sera or specific monoclonal
and polyclonal antibodies. Human sera were initially ti-
trated at 1:25, 1:50 and 1:100 dilutions [30,42]. The 1:100
dilution was chosen for further experiments since it was
the highest serum concentration lacking background re-
activity. After extensive washings, membranes were incu-
bated with goat anti-human IgG or goat anti-mouse or
anti-rabbit IgG peroxidase-conjugated antibodies. The im-
mune complexes were visualized by the Supersignal West
Pico chemiluminescence kit (Pierce, Rockford, IL, USA)
[43]. Criteria of serum positivity toward a given antigen
consisted in the appearance of an immunoreactive bandco-migrating with that detected by the positive control
antibody. The intensity of coloring of the specific immu-
noreactive bands was expressed as densitometric unit (s)
(DU) and was obtained using the NIH Pro-Image 1.5 soft-
ware after blot scanning.
Immunohistochemical analysis
Expression of the C-22 P0 epitope on tissues was determined
by immunoperoxidase staining after incubation with MAb
2B2 or UPC10 (1 μg ⁄mL) as previously described [28,29].
No reactivity was observed using UPC10 (data not shown).
Semiquantitative C-22 P0 epitope expression in human tis-
sues was estimated at x200 magnification in at least 10
fields by two investigators in a blind fashion, who used a
previously described score system with minor modifica-
tions [44,45]. C-22 P0 expression levels (negative, 0; weakly
positive, 1; moderately positive, 2; strongly positive, 3) were
scored. The interobserver reproducibility was >95%. Paraf-
fin sections were also processed for anti-CD3 and anti-
CD20 antibodies analyses using a Ventana XT automated
slide stainer (Ventana Medical Sistem Inc, Roche, Tucson
AZ, USA) according to manufacturer instruction [46,47].
The ratio between anti-CD3+ and anti-CD20+ cells was
evaluated.
Immunofluorescence staining of the C-22 P0 epitope on
colon cancer cell lines (SW260, HT29)
Indirect immunofluorescence was carried out on native
cells. Briefly, cells (5 × 104) were grown for 48 hours with
or without 10% serum. Cells were detached by incubation
with 0.02% EDTA in PBS and incubated with MAb 2B2 or
UPC10 (1 μg/ml) for 1 hour at room temperature [48].
After washes with cold PBS, cells were labeled with goat
anti-mouse IgG Alexa fluor-488-conjugated antibody (Life
Technologies™Molecular Probes, Oregon, USA) for 45 mi-
nutes at room temperature, washed and immediately ob-
served with an Olympus BX51 microscope.
Sulforhodamine B (SRB) assay
For cell proliferation assay, SW260 and HT29 cells (1 × 104
cells/well) were incubated in serum-free RPMI containing
0.2% BSA containing MAb 2B2 (20, 5, 1 μg/ml) or UPC10
(20 μg/ml). MAbs were replenished every 24 h. All treat-
ments were performed in triplicate. Survival of cells was
assessed by the Sulforhodamine B cell proliferation assay
after 72 hours, as previously described [49]. The percentage
survival of the cultures treated with MAb 2B2 was calcu-
lated by normalization of their O.D. values to those of con-
trol cultures treated with UPC10 [50].
Trypan blue exclusion test
For trypan blue exclusion test, SW260 and HT29 cells (5 ×
104cells/well) were seeded in 24-well plates. After 24 hours,
cells were incubated in serum-free RPMI containing 0.2%
Table 1 Clinicopathological characteristics of patients
Patients (number) 72
Age (years)
Media 71
Range 43-87
Gender
Male (number) 42
Female (number) 30
Tumor
Adenoma 5
Colon carcinoma 39
Rectal carcinoma 16
Sigmoid carcinoma 5
Recto-sigmoid carcinoma 7
Stage of disease
I 15
IIA 22
IIB 2
IIIA 1
IIIB 21
IIIC 4
IV 2
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Antibodies were replenished every 24 hours. All treatments
were performed in triplicate. After 72 hours, adherent as
well as suspended cells of each well were harvested and
stained with trypan blue (Sigma, Milan, Italy) and counted
with an optic microscope. The experiments were repeated
three times. Percentage of cell death was determined com-
pared to the total number of cells.
In situ detection of apoptosis
For in situ detection of programmed cell death, SW260
and HT29 cells were seeded at 5 × 104 cells/well in 8-
well chamber-slides. After 24 hours cells were incubated
in serum-free RPMI containing 0.2% BSA and MAb 2B2
(20 μg/ml) or UPC10 (20 μg/ml). Antibodies were
replenished every 24 hours. After 48 hours, cells were
fixed in 4% paraformaldehyde for 15 min, washed and
incubated with the anti-activated caspase-3 polyclonal
antibody for 1 hour. After additional washings the cells
were labeled with a goat anti-rabbit IgG Alexa fluor-
594-conjugated antibody for 30 min [51]. After a third
washing, cells were then incubated with 0.1 μg/ml
Hoechst 33342 and mounted under a coverslip with gly-
cerol. Cells treated for 16 hours with staurosporine
1 μM were used as positive control. The percentage of
apoptotic cells was calculated by determining the ratio
between the cells positive for activated caspase-3 and
the total number of cells present in five randomly
chosen microscopic fields. Cell counts were done in a
blinded fashion.
Statistical analysis
Fisher’s exact test was used to compare the number of
patients with positive levels of antibodies compared to
healthy donors. Variation in the C-22 P0 expression and
in the number of apoptotic cells was evaluated by
Student’s t-test. Statistical associations were considered
significant at a p-value ≤ 0.05.
Data distribution of cell survival and cell death was
preliminarily verified by the Kolmogorov-Smirnov test
and data sets were analyzed by one-way analysis of vari-
ance (ANOVA) followed by Newman-Keuls test. Values
with p ≤ 0.05 were considered significant.
Results
Immunoreactivity of colorectal cancer (CRC) patient sera
to ribosomal P proteins, CEA, EGFR and ErbB2
Sera from colorectal cancer (n = 67) and colon benign
tumor patients (n = 5) were analyzed for the presence of
auto-antibodies to ribosomal P proteins (P0/P1/P2),
CEA, EGFR and ErbB2. The clinicopathological charac-
teristics of patients are reported in Table 1. Patients
serum reactivity was compared to that of healthy donors
(n = 73). To detect antibodies to ribosomal P proteins,the anti-Rib-P Ab ELISA kit was employed. The pres-
ence of serum antibodies to CEA and EGFR or ErbB2
was assessed by western blotting, employing CEA ex-
tracted from tumors, and NIH3T3 cells transfected with
expression vectors encoding for sequences of human
EGFR and ErbB2, respectively. Representative experi-
ments are shown in Figure 1.
None of the sera from healthy donors displayed re-
activity to P proteins (Table 2). Conversely, 7 out of 67
sera from CRC patients reacted to ribosomal P proteins.
The prevalence of anti-P proteins auto-antibodies in
CRC patients was significant compared to that of
healthy donors (p = 0.0048) (Table 2). The antibody re-
sponse to anti-P proteins was not associated with the
stage of disease. Indeed, patients with anti-P proteins
antibodies showed either an early (T1N0, T2N0) or an
advanced stage [T3N0 (n = 2) and 3 patients with T3N1
(n = 3)] of disease. In addition, no antibody response to
ribosomal P proteins was observed in patients with
adenoma.
Conversely, no humoral immune response to CEA was
observed in both colorectal cancer patients and healthy do-
nors (data not shown). The anti-CEA MAb R4 was
employed as a positive control for CEA detection (Table 2).
Two of 67 cancer patients showed antibodies against
EGFR (Table 2). It is important to note that one of these
two patients also had antibodies against ribosomal P
Figure 1 Humoral immune response to ribosomal P proteins, EGFR and ErbB2 in colorectal cancer patients. Analysis of the humoral
immune response to ribosomal P proteins employing the Rib-P Ab ELISA kit (Panel A) and to EGFR and ErbB2 by western blotting employing
NIH3T3 cells coding for EGFR (LTR-EGFR) and ErbB2 (LTR-ErbB2) (Panel B). Pt. = patient; H.D. = healthy donor.
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with cancer of the rectum at an early stage of disease
(T1N0). None of the sera from healthy donors displayed
reactivity to EGFR or ErbB2. Conversely, one of 5 pa-
tients with a benign tumor and one of 67 cancer patients
had antibodies to ErbB2 (Table 2). One patient with an
advanced stage of disease (T3N2b) displayed a simultan-
eous reactivity to EGFR and ErbB2.
Our results indicate that the ribosomal P proteins are
more immunogenic than CEA and ErbB receptors in
CRC patients. The humoral response to P proteins andTable 2 Humoral immune response to ribosomal P proteins, C
Subjects Rib-P proteins (P0/P1/P2) p
Healthy Donors 0/73 n.sa
Patients: Benign tumor 0/5 n.s
Patients: Malignant tumor 7/67 0.0048
an.s = not significant.
bPatients with malignant tumors vs Healthy donors, Fisher’s exact test.the C-22 P0 epitope tumor expression were then further
investigated. In addition, the in vitro effect of MAb 2B2
which recognizes the C-22 P0 epitope on growth of
colon cancer cells was analyzed.
Individual or simultaneous serum reactivity to ribosomal
proteins in colorectal cancer patients
The Anti-Rib-P Ab ELISA kit, containing a mixture of
the three native P0, P1 and P2 ribosomal proteins, does
not allow to identify which P protein is recognized by
serum antibodies. To define the individual P proteinEA, EGFR and ErbB2 in colorectal cancer patients
CEA p EGFR p ErbB2 p
0/73 n.s 0/73 n.s 0/73 n.s
0/5 n.s 0/5 n.s 1/5 n.s
b 0/67 n.s 2/67 n.s 1/67 n.s
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sera, each serum was analyzed for its reactivity to indi-
vidual recombinant ribosomal P proteins (P0, P1 and
P2) by western blotting. Criterion of positivity was the
appearance of an immune-reactive band in the serum
sample, co-migrating with the one visualized by the
MAb 2B2, which recognizes the P0, P1 and P2 proteins.
The reactivity of sera to recombinant ribosomal P pro-
teins is shown in Figure 2. The presence of specific anti-
bodies against ribosomal P proteins is shown in Table 3.
All seven patients had auto-antibodies to P0 protein.
Five patients showed immunoreactivity only to P0, while
two patients had simultaneous auto-antibodies to P0, P1
and P2 proteins. No correlation between the concentra-
tion of auto-antibodies, detected employing the anti-Rib-
P ELISA kit and the density values of immunoreactive
bands with sera by western blotting was observed (data
not shown).
Expression of the C-22 P0 epitope in human normal and
pathological colorectal tissues
To assess the state of the C-22 P0 epitope expression in
tumors, immunohistochemical analysis of colorectal can-
cer tissues was performed by immunostaining with MAb
2B2 and compared to that of adjacent non-neoplastic
mucosa. We evaluated both the intensity and homogen-
eity of the C-22 P0 epitope expression in 23 malignant
tumors and 17 adjacent mucosa samples. Representative
immunostaining of the C-22 P0 epitope is showed in
Figure 3 (Panel A). The C-22 P0 epitope was expressed
homogenously both in the tumor and adjacent normal
mucosa, but the intensity of expression was significantly
higher in the tumor than in the adjacent mucosa (p <
0.001) (Figure 3, Panel B). It is worth noting that the C-22
P0 epitope was found to be also expressed by fibroblasts,
endothelial cells and leukocytes present in the tumor and
the normal mucosa.
Tumor specimens from 5 of the 7 patients positive for
anti-P0 antibodies were analyzed for the expression ofFigure 2 Humoral immune response to individual ribosomal P proteins
blotting. The monoclonal antibody (MAb) 2B2 was used as positive control
fusion proteins GST-P0, GST-P1 and GST-P2. Pt. = patient.tumor infiltrating T and B lymphocytes. Subserosal deep
infiltration of tumor cells was characterized by the pres-
ence of abundant inflammatory cells, with a large preva-
lence of CD3+ T lymphocytes and a small percentage of
CD20+ B lymphocytes (mean ratio 5:1) (Figure 3, Panel C).
Expression and subcellular localization of the C-22 P0 epitope
in colon adenocarcinoma cell lines (SW260 and HT29)
The expression of the C-22 P0 epitope on colon adenocar-
cinoma cells (SW260 and HT29) was analyzed by western
blotting. MAb 2B2 detected a molecular weight product of
38 kDa consistent with the molecular weight of the riboso-
mal P0 protein on both cell lines (Figure 4, Panel A).
We previously demonstrated that the C-22 P0 epitope
is localized on the plasma membrane of not fixed and
not permeabilized tongue and pharynx cancer cells
under conditions of stress, such as the absence of serum
in the culture medium [28]. To determine whether the
serum deprivation induced a similar effect on colon can-
cer cells, SW260 and HT29 cells were grown in the
presence and absence of serum and indirect immuno-
fluorescence was carried out employing MAb 2B2. As
shown in Figure 4, Panel B, SW260 and HT29 cells
grown without serum, have a higher expression of the
C-22 P0 epitope on the plasma membrane compared to
cells cultured in the presence of serum.
Biological effects of MAb 2B2 on colon adenocarcinoma
cells
As shown above, cells under conditions of stress showed
increased expression of the C-22 P0 epitope on the
plasma membrane. Therefore, we examined whether
MAb 2B2 recognizing this epitope was able to inhibit
the growth of colon adenocarcinoma cells. For this pur-
pose, SW260 and HT29 colon cancer cells were seeded
in serum-free culture medium containing 0.2% BSA and
incubated with MAb 2B2 at different concentrations (20,
5 and 1 μg/ml). The antibody UPC10 at 20 μg/ml was
used as matched isotype control antibody.. Analysis of individual ribosomal P proteins was performed by western
. The protein GST was used as a negative control for the recombinant
Table 3 Presence of auto-antibodies directed against
ribosomal P proteins
Patient # Rib-P assay
(U/ml)
Western blotting using
individual recombinant
P proteins
13 13.21 P0, P1, P2
25 10.62 P0
31 10.93 P0
40 14.74 P0, P1, P2
54 10.56 P0
64 50.25 P0
65 14.12 P0
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cell lines in a dose dependent manner compared to con-
trol antibody. When used at higher concentration (20
μg/ml), MAb 2B2 decreased cell growth of 45% in
SW260 cells and 30% in HT29 cells. The mean of the re-
sults of three independent experiments is reported in
Figure 5, Panel A.
A trypan blue exclusion test and in situ detection of
apoptosis were carried out in order to evaluate the effect
of MAb 2B2 on cell death of colon carcinoma cells.
MAb 2B2 significantly increased the percentage of cell
death in a dose dependent manner as compared to con-
trol antibody (UPC10 at 20 μg/ml) (Figure 5, Panel B).
The percentage of cell death upon MAb 2B2 treatmentFigure 3 Expression of the C-22 P0 epitope in normal mucosa and colo
epitope by MAb 2B2. Panel B. Intensity of the C-22 P0 epitope expression in c
semiquantitative evaluation of the C-22 P0 epitope expression in colore
Immunohistochemical detection of CD3+ T lymphocytes and CD20+ B
anti-P0 antibodies (40x).was 11.2% (5 μg/ml) and 19.6% (20 μg/ml) in SW260
cells and 14.1% (5 μg/ml) and 21.9% (20 μg/ml) in HT29
cells.
SW260 and HT29 cells were labeled with an anti-
activated-caspase-3 antibody after treatment with MAb
2B2 (20 μg/ml) or UPC10 (20 μg/ml) for 48 hours or, as
positive control, with staurosporine (1 μM) for 16 hours.
Figure 5, Panel C shows representative pictures of
immunolabeled SW260 and HT29 cells. According to
activated caspase-3 positivity, the treatment with UPC10
had no relevant effect on the induction of apoptosis in
both SW260 (0.3%) and HT29 (0.6%) cells. In compari-
son, the percentage of apoptotic cells was 6.3% (p <
0.001) and 6.2% (p < 0.001) in MAb 2B2-treated SW260
and HT29, respectively. Treatment with staurosporine
resulted in apoptotic rates of 70.1% and 77% in SW260
and HT29, respectively.
Discussion
One of the most important challenges in the fight
against cancer is to find novel biological markers that
can help to improve diagnosis and therapy. Several
tumor antigens are recognized by the immune system
and thus might represent biological markers for the early
detection of cancer [52]. The complexity in the diagnosis
of CRC might be improved by the discovery of new diag-
nostic markers [53]. Several tumor markers have been
identified in CRC [54]. Recently, it has been evaluatedrectal cancer. Panel A. Immunohistochemical detection of the C-22 P0
olorectal tumors and in the adjacent normal mucosa. Bar graph shows a
ctal tumors and the adjacent normal mucosa (p < 0.001). Panel C.
lymphocytes in a colon adenocarcinoma from a patient positive for
Figure 4 Expression and subcellular localization of the C-22 P0
epitope in colon adenocarcinoma cell lines (SW260 and HT29).
Panel A The expression of the C-22 P0 epitope was determined by
western blotting. The recombinant proteins GST-P0/P1/P2 were used
as positive control. Panel B. Indirect immunofluorescence was
performed using not fixed and not permeabilized SW260 and HT29
cells. Cell morphology was determined by phase-contrast microscopy.
The antibody UPC 10 was used as a negative control.
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tigens as a biological marker. It has been described that
auto-antibodies are elicited during the transition from
benign neoplasm or chronic inflammatory disease to
malignancy [55]. Auto-antibodies to CENP-F and P62
appear to be linked to the transition from chronic liver
disease to hepatocellular carcinoma [56]. In our study,
we evaluated the humoral immune response to riboso-
mal P0, P1 and P2 proteins, CEA, EGFR and ErbB2 in
CRC patients and compared to that in healthy donors.
Among the antigens analyzed, the ribosomal P0 protein
was found to be the most immunogenic antigen in CRC
patients. Indeed, patients with CRC showed a significanthumoral response to ribosomal P0 protein compared to
healthy donors. On the other hand, a significant immune
response to CEA, EGFR and ErbB2 was not observed. The
spontaneous immunogenicity of the ribosomal P0 protein
had already been observed in previous studies performed in
our laboratory [28-30]. The analysis of the immune re-
sponse with head and neck cancer patients showed a
significant response against the ribosomal P0 protein. Im-
munity to P0 protein (7/40) was associated with malignancy
and advanced disease stage, but it was not dependent on
the C-22 P0 epitope overexpression [28]. In prostate cancer
patients, a significant humoral response to P0 protein cor-
related with the blood release of the prostate specific anti-
gen (PSA) after radiotherapy [30]. However, in CRC
patients we could not observe any association between the
immune response and the stage of the disease.
Auto-antibodies against P proteins have been identified
for the first time in systemic lupus erythematosus (SLE)
where they can induce damage of the central nervous sys-
tem, hepatitis and nephritis. In particular, anti-P proteins
antibodies appear to be associated with other forms of
SLE with psychosis, where the antibody titer increases be-
fore and during the active phase of psychosis [35]. How-
ever, patients with CRC displaying P0 protein auto-
antibodies, did not show liver or kidney alterations, nei-
ther were affected by psychosis. The lack of normal tissue
damage by spontaneously elicited anti-P0 antibodies in
CRC patients might be due to a low serum auto-
antibodies concentration. Patients with SLE might have a
higher titer of anti-P0 antibodies compared to cancer pa-
tients. In addition, some reports failed to find any relation-
ship of anti-P antibodies and neuropsychiatric SLE or liver
and renal diseases in SLE patients [57,58].
In our study, we also demonstrated, by immunohisto-
chemistry employing MAb 2B2, that the CRC tissue
shows an overexpression of the C-22 P0 epitope com-
pared to adjacent normal mucosa. The C-22 P0 epitope
was found to be overexpressed in head and neck [28],
and breast [29] cancers. In addition earlier studies re-
ported high level of P0 messenger RNA in hepatocellular
and colon carcinomas [36]. In gynecological tumors, the
ribosomal P0 protein expression did not correlate with
the stage of disease although the expression increased
primarily in the cancerous tissue and not in precancer-
ous lesion [59]. The ribosomal protein P0 appears to
promote tumor formation [34]. Indeed, it was observed
that it is able of binding the protein GCIP (interacting
protein cyclin D1 and GRAP2), which is a tumor sup-
pressor localized in the nucleus, which inhibits the phos-
phorylation of RB (retinoblastoma protein). In addition,
P0 also promotes the increased expression of cyclin D1
and cell proliferation, when it is overexpressed [34].
Different monoclonal antibodies have been approved
for the treatment of hematopoietic and solid tumors
Figure 5 Effect of MAb 2B2 recognizing the C-22 P0 epitope on colon adenocarcinoma cells. Panel A. Cells growth was assessed by
sulforhodamine B assay. SW260 and HT29 cells were treated with MAb 2B2 at different concentrations (20, 5, 1 μg/ml). The antibody UPC10 was used as
control (20 μg/ml). The results are the mean of three independent experiments (**p < 0.01, ***p < 0.001). Panel B. Trypan blue exclusion test was
performed to determine the percentage of cell death of SW260 and HT29 cells treated with MAb 2B2 at different concentrations (20, 5, 1 μg/ml) or with
the antibody UPC10 (20 μg/ml). The results are the mean of three independent experiments (***p < 0.001). Panel C. In situ detection of apoptosis.
Induction of apoptosis in SW260 and HT29 cells, as assessed by immunolabeling with an anti-activated caspase-3 antibody, after treatment with MAb
2B2 (20 μg/ml) or UPC10 (20 μg/ml) for 48 hours or, as positive control, with staurosporine (1 μM) for 16 hours. Nuclei were counterstained
with Hoechst.
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cancer cells compared to the normal counterparts and
block directly or through immune system the growth of
cancer cells [60]. Accordingly, we evaluated the C-22 P0
epitope expression on the plasma membrane of colon
cancer cells, since we earlier demonstrated that this epi-
tope is expressed on the membrane of tongue and phar-
ynx cancer cells under conditions of stress [28]. We
observed that colon cancer cells grown without serum,
showed a higher expression of the C-22 P0 epitope on
the plasma membrane compared to cells cultured in the
presence of serum. It should be considered that solid tu-
mors could grow in an adverse microenvironment char-
acterized by improper vascularization and poor oxygen
and nutrient supply [61]. In addition, it was demon-
strated that the ribosomal P0 protein is expressed in the
membrane in Jurkat cells and T-lymphoblasts, and be-
comes the target for anti-P0 auto-antibodies, which were
internalized and caused cell apoptosis [62]. Anti-P0 anti-
bodies were shown to penetrate into living hepatoma
cells and cause cellular dysfunction in culture as well
[63,64]. We previously demonstrated that BALB-neuT
mice vaccinated with the human P0 protein had a sig-
nificant delay of neu-mediated mammary carcinoma
growth and that the extent of tumor growth interferencein vivo was associated with high serum levels of anti-
bodies, which recognize the murine P0 protein
expressed on mouse mammary cancer cells [29].
Accordingly, we evaluated the biological effect of MAb
2B2 on the in vitro growth of cancer cells. Here, we
demonstrated that MAb 2B2 significantly inhibited hu-
man colon adenocarcinoma cell growth in a dose
dependent manner. The inhibition of survival observed
in MAb 2B2-treated cells could be due to both reduced
proliferation and increased cell death. Therefore, we an-
alyzed the effect of MAb 2B2 on colon cancer cells via-
bility and apoptosis. We demonstrated that MAb 2B2
significantly reduced colon cancer cell viability and in-
duced apoptosis in a dose dependent manner in both
colon cancer cell lines.
Overall, our results indicate the potential usefulness of
the ribosomal P0 protein as an immunological target in
CRC patients, who spontaneously develop auto-antibodies
to the P0 protein. Further studies should be performed to
study the potential involvement of anti P0 auto-antibodies
in cancer cells death. Our study showing for the first time
a spontaneous humoral immune response to ribosomal P0
protein in CRC patients and the inhibition of in vitro can-
cer cell growth after C-22 P0 epitope targeting, might
offer a potential tool for designing cancer vaccines
Benvenuto et al. Journal of Translational Medicine  (2015) 13:101 Page 10 of 11targeting the P0 protein, in order to enhance the immune
response for hampering tumor growth.
Conclusions
Our study shows for the first time a spontaneous humoral
immune response to ribosomal P0 protein in CRC pa-
tients and the inhibition of in vitro cancer cell growth
after C-22 P0 epitope targeting. The ribosomal P0 protein
might be a useful immunological target in CRC patients.
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